Body Weight Cutoff for Daily Dosage of Efavirenz and 60-Week Efficacy of Efavirenz-Based Regimen in Human Immunodeficiency Virus and Tuberculosis Coinfected Patients Receiving Rifampin

Seventy-one human immunodeficiency virus-infected patients with tuberculosis who were receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C(12)) were monitored....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Manosuthi, Weerawat, Sungkanuparph, Somnuek, Tantanathip, Preecha, Mankatitham, Wiroj, Lueangniyomkul, Aroon, Thongyen, Supeda, Eampokarap, Boonchuay, Uttayamakul, Sumonmal, Suwanvattana, Pawita, Kaewsaard, Samroui, Ruxrungtham, Kiat
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology (ASM) 2009
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2764182/
https://ncbi.nlm.nih.gov/pubmed/19667281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00492-09
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars